In a significant move, the Union Cabinet has given the green light to the National Policy on Research and Development and Innovation in the Pharma-MedTech Sector. This decision is accompanied by the approval of the Scheme for Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP), with a substantial allocation of Rs 5,000 crore for a five-year period spanning from FY24 to FY28.
The scheme was rolled out earlier this month by the government with the belief that the Indian pharmaceutical industry has the potential to increase its current 3.4 per cent share of the global market to 5 per cent by the year 2030.
The National Policy focuses on three key areas: strengthening the regulatory framework, incentivising investment in innovation, and enabling an ecosystem for innovation and research. The policy aims to accelerate drug discovery and development, foster collaboration between industry and academia, and streamline existing policies to optimise research resources.
The PRIP scheme, with an allocation of Rs 5,000 crore, focuses on two components: the establishment of Centres of Excellence (CoEs) within existing institutions to strengthen research infrastructure, and promotion of research in priority areas. These priority areas encompass a range of fields such as new chemical and biological entities, precision medicines, medical devices, and antimicrobial resistance solutions.
Research and development in the pharmaceutical and medical technology sectors within public institutions are currently spread across different research departments and institutions. The policy aims to encourage coordination among industry and academia to improve efficiency.
India boasts the world's third-largest pharmaceutical industry by volume, valued at around $50 billion. While the Indian sector has supplied affordable and high-quality generic drugs globally, it faces challenges such as import dependence on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), lagging development of biologics, biosimilars and other emerging products, and low technological capacities.
Also Read
ArcelorMittal looks to rope in Indian climate tech start-ups to go green
Madhya Pradesh election 2023: Shivraj Singh Chouhan to expand cabinet today
An ode to start-ups in defence
Pride of place: How to choose the perfect display cabinet for home
Rajasthan cabinet approves creation of 19 new districts, three divisions
Centre announces up to Rs 50 lakh grant for technical textiles startups
Rice shipments of 500,000 tonnes postponed after new duty: Exporters
Centre plans to announce PM e-Bus Sewa guidelines within a month
Centre cuts LPG cylinders price by Rs 200 for PMUY beneficiaries
As India pushes to make rupee international, UCO Bank is in a sweet spot
The scheme is set to stimulate collaboration between pharmaceutical companies, research institutions, and start-ups. It will extend support to established pharmaceutical companies and start-ups alike.
The policy's approach, along with the scheme, is projected to yield benefits such as reducing import dependence, improving overall healthcare indices, creating high-end research and innovation jobs, fostering collaboration, and developing world-class research infrastructure.